drugset / Trial / NCT01154153
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (\>=2 to \<12 years old) with allergic rhinitis (AR).
Timeline
- Start
- 2010-06
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triamcinolone Acetonide | Other / unclassified | 110 ug | Intranasal |
| Subject | Triamcinolone Acetonide | Other / unclassified | 220 ug | Intranasal |
| Background | Loratadine | Small molecule | 5 mg | Oral |